PT977565E - Composicao farmaceutica compreendendo um composto triciclico com melhor estabilidade absorvibilidade e um potencial de irritacao reduzido - Google Patents
Composicao farmaceutica compreendendo um composto triciclico com melhor estabilidade absorvibilidade e um potencial de irritacao reduzidoInfo
- Publication number
- PT977565E PT977565E PT98904366T PT98904366T PT977565E PT 977565 E PT977565 E PT 977565E PT 98904366 T PT98904366 T PT 98904366T PT 98904366 T PT98904366 T PT 98904366T PT 977565 E PT977565 E PT 977565E
- Authority
- PT
- Portugal
- Prior art keywords
- absorbability
- pharmaceutical composition
- better stability
- irritation potential
- reduced irritation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Reproductive Health (AREA)
- Transplantation (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP3617297 | 1997-02-20 | ||
| JP25635797 | 1997-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT977565E true PT977565E (pt) | 2004-01-30 |
Family
ID=26375217
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98904366T PT977565E (pt) | 1997-02-20 | 1998-02-18 | Composicao farmaceutica compreendendo um composto triciclico com melhor estabilidade absorvibilidade e um potencial de irritacao reduzido |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US6387918B1 (pt) |
| EP (1) | EP0977565B1 (pt) |
| JP (1) | JP3396888B2 (pt) |
| KR (1) | KR100490357B1 (pt) |
| CN (1) | CN1178656C (pt) |
| AR (1) | AR011846A1 (pt) |
| AT (1) | ATE237325T1 (pt) |
| AU (1) | AU727337B2 (pt) |
| BR (1) | BR9807234B1 (pt) |
| CA (1) | CA2282345C (pt) |
| DE (1) | DE69813542T2 (pt) |
| DK (1) | DK0977565T3 (pt) |
| EA (1) | EA003580B1 (pt) |
| ES (1) | ES2193515T3 (pt) |
| HK (1) | HK1027957A1 (pt) |
| HU (1) | HU226163B1 (pt) |
| IL (1) | IL131298A (pt) |
| NO (1) | NO325103B1 (pt) |
| PT (1) | PT977565E (pt) |
| TW (1) | TW450810B (pt) |
| WO (1) | WO1998036747A1 (pt) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2326222C (en) * | 1998-04-27 | 2008-09-23 | Fujisawa Pharmaceutical Co., Ltd. | Medicinal compositions |
| GB9817064D0 (en) * | 1998-08-05 | 1998-10-07 | Fujisawa Pharmaceutical Co | New use |
| US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| US20030018044A1 (en) * | 2000-02-18 | 2003-01-23 | Peyman Gholam A. | Treatment of ocular disease |
| AUPR529701A0 (en) * | 2001-05-28 | 2001-06-21 | Fujisawa Pharmaceutical Co., Ltd. | Pharmaceutical composition |
| NZ532769A (en) | 2001-11-29 | 2005-12-23 | 3M Innovative Properties Co | Pharmaceutical formulations comprising an immune response modifier |
| AU2003272471B2 (en) * | 2002-09-18 | 2010-10-07 | Trustees Of The University Of Pennsylvania | Method of inhibiting choroidal neovascularization |
| US7994214B2 (en) | 2003-08-29 | 2011-08-09 | Lifecycle Pharma A/S | Solid dispersions comprising tacrolimus |
| ATE531368T1 (de) | 2003-08-29 | 2011-11-15 | Veloxis Pharmaceuticals As | Tacrolimus enthaltende zusammensetzungen mit modifizierter freisetzung |
| CN102144961A (zh) * | 2003-09-18 | 2011-08-10 | 参天制药株式会社 | 经巩膜递送 |
| BRPI0608152A2 (pt) * | 2005-02-09 | 2009-11-10 | Macusight Inc | formulações para tratamento ocular |
| US8663639B2 (en) * | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| KR20140093764A (ko) | 2006-02-09 | 2014-07-28 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| US7672006B2 (en) * | 2006-02-22 | 2010-03-02 | Xerox Corporation | Multi-marking engine printing platform |
| CN103127100A (zh) * | 2006-03-23 | 2013-06-05 | 参天制药株式会社 | 用于与血管通透性有关的疾病或病症的制剂和方法 |
| US20100286122A1 (en) * | 2006-04-10 | 2010-11-11 | Kevin Belyk | CGRP Antagonist Salt |
| US20080265343A1 (en) * | 2007-04-26 | 2008-10-30 | International Business Machines Corporation | Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof |
| EP2167033B1 (en) | 2007-05-30 | 2017-04-19 | Veloxis Pharmaceuticals A/S | Once daily oral dosage form comprising tacrolimus |
| CA2738831C (en) | 2008-10-08 | 2016-05-24 | Takata Seiyaku Co., Ltd. | Tacrolimus preparation for external applications |
| HUE028847T2 (en) | 2010-02-17 | 2017-01-30 | Veloxis Pharmaceuticals As | Stabilized tacrolimus preparation |
| JP5674786B2 (ja) * | 2010-07-23 | 2015-02-25 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
| WO2012011192A1 (ja) * | 2010-07-23 | 2012-01-26 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
| CN103974700B (zh) * | 2011-12-07 | 2015-12-09 | 久光制药株式会社 | 贴附剂 |
| WO2013111817A1 (ja) * | 2012-01-25 | 2013-08-01 | マルホ株式会社 | タクロリムスを含有する水中油型クリーム状組成物 |
| AU2016308568A1 (en) | 2015-08-19 | 2018-02-22 | Vivus Llc | Pharmaceutical formulations |
| WO2018237218A1 (en) | 2017-06-23 | 2018-12-27 | The Procter & Gamble Company | COMPOSITION AND METHOD FOR ENHANCING SKIN APPEARANCE |
| WO2019233722A1 (en) | 2018-06-08 | 2019-12-12 | Almirall, S.A. | Pharmaceutical composition comprising tacrolimus |
| EP3817717A1 (en) | 2018-07-03 | 2021-05-12 | The Procter & Gamble Company | Method of treating a skin condition |
| CN115843238A (zh) | 2020-06-01 | 2023-03-24 | 宝洁公司 | 改善维生素b3化合物渗透到皮肤中的方法 |
| US10959933B1 (en) | 2020-06-01 | 2021-03-30 | The Procter & Gamble Company | Low pH skin care composition and methods of using the same |
| CA3212370A1 (en) | 2021-03-03 | 2022-09-09 | Sana Biotechnology, Inc. | Immunosuppressive therapies for use with cardiomyocyte cell therapies, and associated methods and compositions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE66485B1 (en) * | 1989-07-05 | 1996-01-10 | Fujisawa Pharmaceutical Co | Aqueous liquid composition for external use |
| ATE150304T1 (de) | 1990-09-04 | 1997-04-15 | Fujisawa Pharmaceutical Co | Tricyclische verbindungen enthaltende salben |
| CA2054983A1 (en) * | 1990-11-08 | 1992-05-09 | Sotoo Asakura | Suspendible composition and process for preparing the same |
| JPH06183970A (ja) | 1992-12-16 | 1994-07-05 | Fujisawa Pharmaceut Co Ltd | 医薬用組成物 |
| JPH06345646A (ja) * | 1993-06-08 | 1994-12-20 | Fujisawa Pharmaceut Co Ltd | ローション剤 |
| PL184750B1 (pl) | 1994-10-26 | 2002-12-31 | Novartis Ag | Kompozycja w postaci emulsji do stosowania miejscowego |
-
1998
- 1998-02-17 TW TW087102169A patent/TW450810B/zh not_active IP Right Cessation
- 1998-02-18 KR KR10-1999-7007087A patent/KR100490357B1/ko not_active IP Right Cessation
- 1998-02-18 CA CA002282345A patent/CA2282345C/en not_active Expired - Fee Related
- 1998-02-18 HU HU0000979A patent/HU226163B1/hu not_active IP Right Cessation
- 1998-02-18 CN CNB988043440A patent/CN1178656C/zh not_active Expired - Fee Related
- 1998-02-18 DE DE69813542T patent/DE69813542T2/de not_active Expired - Lifetime
- 1998-02-18 WO PCT/JP1998/000665 patent/WO1998036747A1/en active IP Right Grant
- 1998-02-18 ES ES98904366T patent/ES2193515T3/es not_active Expired - Lifetime
- 1998-02-18 DK DK98904366T patent/DK0977565T3/da active
- 1998-02-18 IL IL13129898A patent/IL131298A/en not_active IP Right Cessation
- 1998-02-18 EP EP98904366A patent/EP0977565B1/en not_active Expired - Lifetime
- 1998-02-18 EA EA199900749A patent/EA003580B1/ru not_active IP Right Cessation
- 1998-02-18 BR BRPI9807234-0B1A patent/BR9807234B1/pt not_active IP Right Cessation
- 1998-02-18 AU AU62289/98A patent/AU727337B2/en not_active Ceased
- 1998-02-18 PT PT98904366T patent/PT977565E/pt unknown
- 1998-02-18 AT AT98904366T patent/ATE237325T1/de active
- 1998-02-18 US US09/367,698 patent/US6387918B1/en not_active Expired - Lifetime
- 1998-02-18 JP JP53648298A patent/JP3396888B2/ja not_active Expired - Lifetime
- 1998-02-20 AR ARP980100785A patent/AR011846A1/es active IP Right Grant
-
1999
- 1999-08-19 NO NO19994003A patent/NO325103B1/no not_active IP Right Cessation
-
2000
- 2000-10-31 HK HK00106933A patent/HK1027957A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT977565E (pt) | Composicao farmaceutica compreendendo um composto triciclico com melhor estabilidade absorvibilidade e um potencial de irritacao reduzido | |
| DE69833464D1 (de) | Pharmazeutische Zusammensetzung, enthaltend 2,3-Diaryl-PyrazoloÄ1,5-bÜPyridazin Derivate | |
| EE200100022A (et) | Tiobensimidasooli derivaadid ja farmatseutiline kompositsioon | |
| DE69821457D1 (de) | Zusammensetzungen mit kontrollierter Wirkstoffabgabe | |
| EE04440B1 (et) | Kaparetseptori opioidpeptiidid ja farmatseutilinekompositsioon | |
| BRPI9810519B1 (pt) | derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos. | |
| ID24654A (id) | Formulasi farmasi omeprazola | |
| EE200000098A (et) | Farmatseutiline kompositsioon piperidinoalkanooldekongestandi kombineerimiseks | |
| ATE222751T1 (de) | Pharmazeutische aerosolzusammensetzung | |
| NO20004345L (no) | Farmasøytisk sammensetning | |
| DE69810189T2 (de) | Zusammensetzungen mit kontrollierter Wirkstoffabgabe | |
| DE59801987D1 (de) | Pharmazeutische zusammensetzung enthaltend peptichemio | |
| EE9900545A (et) | Farmatseutiline kompositsioon | |
| DE69614407D1 (de) | Pharmazeutische zusammensetzungen | |
| ID29294A (id) | Komposisi farmasi | |
| ATE208364T1 (de) | A-oxo-butansäuren enthaltende pharmazeutische zusammensetzung | |
| LV11727A (lv) | Farmaceitiska kompozicija | |
| ID25857A (id) | Komposisi farmasi | |
| FI973280A (fi) | Farmaseuttinen koostumus | |
| BR9710568A (pt) | Composi- o farmac-utica contendo um antagonista 5Hht2c e um antagonista d2 | |
| BR9605777A (pt) | Composição farmacêutica | |
| ID23531A (id) | Komposisi farmasi | |
| BR9605131A (pt) | Composição farmacêutica | |
| BR1101151A (pt) | Compostos e composição farmacêutica | |
| FI960435A (fi) | Lääkkeiden transdermaalisen antotapaan tarkoitettu koostumus |